摘要：2025年9月19日-21日，由上海市医学会、上海市医学会感染与化疗专科分会主办，中国医药教育协会临床微生物学专业委员会协办，复旦大学附属华山医院抗生素研究所承办的第十六届全国感染性疾病及抗微生物化疗学术会议暨2025年上海市医学会感染与化疗分会学术会议、中国
转自：复星医药
2025年9月19日-21日，由上海市医学会、上海市医学会感染与化疗专科分会主办，中国医药教育协会临床微生物学专业委员会协办，复旦大学附属华山医院抗生素研究所承办的第十六届全国感染性疾病及抗微生物化疗学术会议暨2025年上海市医学会感染与化疗分会学术会议、中国医药教育协会临床微生物学专委会首届学术会议圆满举行。来自全国感染、呼吸、重症、血液、风湿、肾病、儿科、外科、妇科、临床药学、临床药理、临床微生物学、医院感染控制等多学科领域的专家和同道相聚上海，分享感染性疾病诊治、抗菌药物合理应用和细菌耐药防治的前沿进展。会议期间共有近800名医学同道线下注册参会。
复红康合医药江苏有限公司正在推进中的全球三期临床研发产品Nacubactam（OP0595）受到关注。
大会开幕式后，复旦大学附属华山医院抗生素研究所所长王明贵教授首先做《抗菌新药研发进展及临床合理应用与管理》报告，他梳理了全球抗菌新药研发现状，结合我国抗菌药物管理政策，阐述如何通过规范用药指征、优化给药方案，实现抗菌药物合理应用，报告中也列举了近年来获批及在研的抗菌药物进展，并提到头孢吡肟/Nacubactam和氨曲南/Nacubactam两种联用组合在针对不同类型碳青霉烯酶时的作用特点。
9月21日，复旦大学附属华山医院抗生素研究所副所长黄海辉教授作了题为《新型β-内酰胺酶抑制剂的研发进展》的报告。她回顾了细菌耐药的严峻挑战，以及近年来新型β-内酰胺酶抑制剂代表性化合物的特点及其临床研究进展。黄教授指出，Nacubactam不同于已上市的β-内酰胺酶抑制剂，具备多重作用机制，这一机制在体外临床分离株中显示出明显优势。我们看到全球与中国的耐药监测数据以及部分公开的临床数据呈现良好结果，期待早日看到Nacubactam的全球多中心临床数据。
黄海辉教授做专题会报告
关于复红康合
复星医药与丸红的合资公司。公司成立于2018年，总部设在江苏泰州并在上海设有分公司。迄今为止，公司已经成功协同多家日本制药企业在中国进行产品的开发和商业化。OP0595在中国境内（不包括港澳台）的临床开发由复红康合负责执行。作为中日两国的友好合作桥梁，以及在医药医疗创新领域的排头兵，公司一直以来秉承为更多患者提供高品质的治疗产品及服务的目标，致力于为中日两国患者带来更多创新医疗健康产品。
Nacubactam (OP0595) Showcased at the National Conference on Anti-infective Therapy
From September 19-21, 2025, The 16th Academic Conference on Infectious Diseases and Antimicrobial Chemotherapy, The 1st National Academic Conference on Clinical Microbiology, and The 2025 Shanghai Medical Association's Annual Conference on Infection and Chemotherapy, hosted by the Shanghai Medical Association, and organized by Society for Clinical Microbiology of Chinese Medicine Education Association, Society of Infection and Chemotherapy, Shanghai Medical Association were convened in Shanghai. Nearly 800 medical professionals from across the country in infectious diseases, respiratory medicine, critical care, hematology, rheumatology, nephrology, pediatrics, surgery, gynecology, clinical pharmacy, clinical pharmacology, clinical microbiology, and hospital infection control gathered in Shanghai to share the latest advances in the diagnosis and treatment of infectious diseases, rational use of antimicrobials, and strategies for combating antimicrobial resistance.
Nacubactam (OP0595), now in global Phase III clinical trials and under development by Fobeni Healthcom Pharmaceutical Jiangsu Co., Ltd., has attracted wide interest.
Following the opening ceremony, Professor Wang Minggui, Director of the Institute of Antibiotics at Huashan Hospital, Fudan University, delivered a keynote lecture titled “Progress in Antibacterial Drug Development and Rational Management of Clinical Application.” He reviewed the current landscape of global antibacterial drug development and, in the context of China’s antimicrobial stewardship policies, explained how rational use can be achieved through optimized indications and dosing strategies. His report also highlighted the progress of newly approved and investigational antibacterial agents in recent years, including the combination regimens of Cefepime-Nacubactam and Aztreonam-Nacubactam, discussing their roles against different types of carbapenemases.
On September 21, Professor Huang Haihui, Deputy Director of the Institute of Antibiotics at Huashan Hospital, gave a presentation entitled “Advances in the Development of Novel β-lactamase Inhibitors.” She reviewed the serious challenges posed by bacterial resistance, summarized the characteristics and clinical progress of representative novel β-lactamase inhibitors in recent years, and emphasized that Nacubactam is distinct from approved β-lactamase inhibitors, possessing multiple mechanisms of action that demonstrate clear advantages against clinical isolates in vitro. Building on this, encouraging results have also been observed from global and Chinese antimicrobial resistance surveillance as well as from publicly available clinical data, and there is broad anticipation for the upcoming global multicenter clinical results of Nacubactam.
About Fobeni
Fobeni Healthcom Pharmaceutical Jiangsu Co., Ltd. is a joint venture between Fosun Pharma and Marubeni Corporation. Founded in 2018, the company is headquartered in Taizhou, Jiangsu Province, with a branch office in Shanghai. To date, the company has successfully collaborated with multiple Japanese pharmaceutical enterprises to advance product development and commercialization in China. The clinical development of OP0595 in China (excluding Hong Kong, Macao, and Taiwan) is led by Fobeni. As a bridge of friendly cooperation between China and Japan and a pioneer in pharmaceutical and medical innovation, the company remains committed to providing high-quality therapeutic products and services to more patients, striving to bring innovative healthcare solutions to patients in both countries.
来源：新浪财经
